Loading…
← CockpitCompetitor Analysis › 300485.SZ Beijing Science Sun Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Beijing Science Sun Pharmaceutical Co., Ltd. Class A300485.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 31
Mkt cap
$517M
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$4.20M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-6.1 pp
WACC 6.3%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥7.25
1D-0.7%
1W-7.0%
1M-7.0%
3M-28.4%
6M-28.6%
YTD-31.5%
1Y-41.4%
ATR %3.6%
52w lowhigh47.5% off high

What Beijing Science Sun Pharmaceutical does

Employees: 489

Beijing Science Sun Pharmaceutical at a glance

Size Beijing Science Sun Pharmaceutical (300485.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $517M, the 3619th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.25 on 18 Nov 2026.

Performance Over six months the shares fell 28.6%, against -16.0% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 19 in its peer set.

Growth Revenue fell 10.6% over the last twelve months (peer median +11.6%); the operating margin is -8.2% (peer median 11.2%).

Valuation It trades at 5.6× enterprise value to sales against a peer median of 3.9× (7th most expensive of 19).

Capital Return on invested capital runs 6.1 points below its cost of capital (6.3% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 84300485.SZ 72
Six months, rebased to 100: Beijing Science Sun Pharmaceutical against the median of its 20 peers (local-currency closes).

Beijing Science Sun Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥359MCN¥401MCN¥415MCN¥474MCN¥730M
Revenue growth—-3%-13%-35%—
Gross profitCN¥255MCN¥244MCN¥258MCN¥317MCN¥542M
EBITDAn/aCN¥30.1MCN¥69.9MCN¥8.45MCN¥71.4M
Net income-CN¥167MCN¥14.6M-CN¥68.9MCN¥103MCN¥205M
Free cash flow-CN¥52.1M-CN¥30.9MCN¥60.1M-CN¥16.1MCN¥107M
Capital expenditureCN¥90.7MCN¥100MCN¥101MCN¥52.9MCN¥43.3M
Total debtCN¥29.0MCN¥19.7MCN¥0CN¥0CN¥0

Quarterly statements and history in the cockpit →

Beijing Science Sun Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%603676EGTXSUPRIYA000919INDPGUJTHEM603222GYRE600222SENORESTKNO600513003090AARTIDRUGSMOREPENLAB1666300485.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Science Sun Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×25×50×75×603676EGTXEVONILESUPRIYA000919GUJTHEM603207603222GYRESENORESTKNO600513003090MOREPENLAB0021071666300485.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Science Sun Pharmaceutical is the large dot.

Beijing Science Sun Pharmaceutical competitors and peer comparison

How Beijing Science Sun Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Science Sun Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300485.SZPeer medianRank in peer set
1-month return-7.0%-7.0%10th lowest of 20
6-month return-28.6%-16.0%3rd lowest of 19
Distance from 52-week high-47.5%-38.7%4th lowest of 20
Revenue growth (TTM)-10.6%+11.6%2nd lowest of 19
Operating margin-8.2%11.2%5th lowest of 19
EV / Sales5.6×3.9×7th most expensive of 19
ROIC minus cost of capital-6.1 pp-2.7 pp5th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%5.6×n/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%2.3×-6.1%+9.6%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%71.0×n/an/a
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%16.2×49.3%-1.5%
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%5.5×28.2%+15.8%
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%0.7×2.4%+5.0%
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%27.2×n/an/a
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%4.8×-5.4%+7.6%
Chimin Health Management 603222.SSChina$533M-31%+1%-28%6.6×n/an/a
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%4.0×n/an/a
Henan Taloph Pharmaceutical Stock 600222.SSChina$497M-21%-5%7%2.5×16.7%+4.4%
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a
Alpha Teknova TKNOUnited States$496M+113%+15%-32%11.0×n/an/a
Jiangsu Lianhuan Pharmaceutical 600513.SSChina$496M-41%+14%0%1.8×n/an/a
Daewoong 003090.KSSouth Korea$495M-28%+6%11%0.9×n/an/a
Aarti Drugs AARTIDRUGS.NSIndia$494M+34%+15%11%1.8×22.1%+3.5%
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%2.2×n/an/a
Shandong Wohua Pharmaceutical 002107.SZChina$493M-20%-4%18%3.7×5.9%-4.1%
Tong Ren Tang Technologies 1666.HKHong Kong$491M-19%-14%12%0.6×-17.2%+6.3%

Questions

Which companies are Beijing Science Sun Pharmaceutical's closest peers?
The cockpit's peer set: Xizang Weixinkang Pharmaceutical (603676.SS), Egetis Therapeutics (EGTX.ST), Evonile Pharma (EVONILE.NS), Supriya Lifescience (SUPRIYA.NS), Jinling Pharmaceutical (000919.SZ), Indaptus Therapeutics (INDP), Gujarat Themis Biosyn (GUJTHEM.NS), Electra Therapeutics (ETRA).
Is Beijing Science Sun Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 5.6× against a peer median of 3.9×, 7th most expensive of 19 in its peer set.
How has Beijing Science Sun Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -28.6% against -16.0% for the median peer; over one year -41.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.